# OAK (NCT02008227)

> A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy

No report yet. It can be ordered.

- Drugs tested: atezolizumab
- Indication: locally advanced or metastatic non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02008227
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Non-Squamous Non-Small Cell Lung Cancer
- Interventions: Atezolizumab; Docetaxel
- Enrollment: 1225
- Primary outcome: Percentage of Participants Who Died: PP-ITT
- Primary outcome: Percentage of Participants Who Died: Tumor Cells (TC)1/2/3 or Tumor-Infiltrating Immune Cells (IC)1/2/3 Subgroup of PP
- Primary outcome: Overall Survival (OS): PP-ITT
- Primary outcome: OS: TC1/2/3 or IC1/2/3 Subgroup of PP
- Primary outcome: OS: SP-ITT
- Primary outcome: OS: TC1/2/3 Or IC1/2/3 Subgroup of SP
- Primary outcome: OS: TC2/3 or IC2/3 Subgroup of SP
- Primary outcome: OS: TC3 or IC3 Subgroup of SP

## Questions raised in the commentary

_Automated from all 25 indexed sources (Jun 2017 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether continuing atezolizumab beyond progression improves outcomes
- Which patients may benefit from immunotherapy beyond progression
- Whether blood TMB predicts benefit, and which cutoff is meaningful

Also discussed: EGFR/ALK alterations, PD-L1 assay interpretation.

## Indexed commentary on OAK so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 16
- Podcasts: 7
- YouTube: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=oak-nct02008227

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02008227", "email": "<work email>"}; the inbox owner confirms by the emailed link.